ACP-103, a 5-HT2A receptor inverse agonist: Safety, tolerability, and pharmacokinetics in healthy volunteers

被引：0
|
作者：
Vanover, KE
Weiner, DM
Schlienger, N
Thygesen, M
Tolf, B
Hacksell, U
Brann, MR
Davis, RE
机构：
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2004年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S253 / S253
页数：1
相关论文
共 50 条
  • [1] The tolerability of ACP-103, a 5-HT2A receptor inverse agonist in Parkinson's disease patients
    Weiner, DM
    Vanover, KE
    Hacksell, U
    Brann, MR
    Davis, RE
    MOVEMENT DISORDERS, 2005, 20 : S72 - S72
  • [2] Drug evaluation:: ACP-103, a 5-HT2A receptor inverse agonist
    Roberts, Claire
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (07) : 653 - 660
  • [3] ACP-103, a 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia
    Vanover, Kimberly E.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 43 - 43
  • [4] ACP-103, a potent 5-HT2A receptor inverse agonist, as an adjunctive therapy in schizophrenia
    Vanover, Kimberly E.
    Lameh, Jelveh
    Gardell, Luis R.
    Ott, Thomas R.
    Ma, Jian-Nong
    Burstein, Ethan S.
    van Kammen, Daniel
    Davis, Robert E.
    Weiner, David M.
    Brann, Mark R.
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 80 - 80
  • [5] PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
    Nordstrom, Anna-Lena
    Mansson, Mattias
    Jovanovic, Hristina
    Karlsson, Per
    Halldin, Christer
    Farde, Lars
    Vanover, Kimberly E.
    Hacksell, Uli
    Brann, Mark R.
    Davis, Robert E.
    Weiner, David M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (02): : 163 - 171
  • [6] ACP-103, a 5-HT2A receptor inverse agonist, a novel potential treatment for psychosis
    Vanover, KE
    Weiner, DM
    Harvey, SC
    Powell, SB
    Geyer, MA
    Andersson, CM
    Tolf, BR
    Hacksell, U
    Brann, MR
    Davis, RE
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 317 - 317
  • [7] ACP-103 -: 5-HT2A receptor inverse agonist -: Treatment of psychosis -: Treatment of sleep disorders
    Wang, Y.
    Bolos, J.
    Serradell, N.
    DRUGS OF THE FUTURE, 2006, 31 (11) : 939 - 943
  • [8] Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers
    Vanover, Kimberly E.
    Robbins-Weilert, Doris
    Wilbraham, Darren G.
    Mant, Timothy G. K.
    van Kammen, Daniel P.
    Davis, Robert E.
    Weiner, David M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (06): : 704 - 714
  • [9] ACP-103, a novel 5-HT2A receptor inverse agonist, improves the efficacy and side effect profile of haloperidol in experimental models
    Gardell, LR
    Barido, RL
    Pounds, L
    Johnson, RW
    Anderson, GT
    Veinbergs, I
    Bonhaus, DW
    Hacksell, U
    Brann, MR
    Davis, RE
    Vanover, KE
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 49 - 49
  • [10] A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
    Vanover, Kimberly E.
    Betz, Adrienne J.
    Weber, Suzanne M.
    Bibbiani, Francesco
    Kielaite, Aiste
    Weiner, David M.
    Davis, Robert E.
    Chase, Thomas N.
    Salamone, John D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, 90 (04) : 540 - 544
12345